This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

PHOSP-COVID [COVID-19] [UPH]

  • Research type

    Research Study

  • Full title

    Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes

  • IRAS ID

    285439

  • Contact name

    Christopher Brightling

  • Contact email

    ceb17@le.ac.uk

  • Sponsor organisation

    University of Leicester

  • ISRCTN Number

    ISRCTN10980107

  • Duration of Study in the UK

    26 years, 0 months, 18 days

  • Research summary

    The COVID-19 pandemic has had a major impact on the UK’s health, social care and\neconomy. The long-term sequelae of COVID-19 after discharge from hospital in both\nthose with and without comorbidities are unknown. A comprehensive patient-centred holistic study is required to determine the chronic health and health economic sequelae of COVID-19 infection in post-hospitalisation survivors. This will define\ndemographic, clinical and molecular biomarkers of the susceptibility and inform our\nunderstanding of the impact of interventions during the acute illness. These insights will guide consequent in-depth studies to inform precision medicine in at risk groups by directing new clinical trials and care for current and future post-COVID-19 patients. \n\nThis study has been approved as part of the NIHR Urgent Public Health review. The study shall recruit individuals post-hospitalisation with a COVID-19\ndischarge diagnosis to study the short (0-3 months), medium (3-6 months) and long (6-12 months) effects of the disease. The study will analyse routine clinical data with linkage to retrospective and prospective health and social care records (Tier 1), enhanced clinical data and research-specific biosampling (Tier 2) and re-call of participants by genotype and phenotype for more detailed studies (Tier 3). Tier 2 participants for whom further clinical assessments are recommended may also be asked to provide additional samples and data (Tier 2 research) and will have their records extracted from those time-points.\n\nThe study will recruit 10000 individuals with a minimum of 4000 in Tier 2. The study will continue to link to participants clinical data for at least 25 years or until the patient has deceased or withdrawn consent.\n\nThe clinical study is underpinned by world-leading Universities, NIHR infrastructure e.g. BRCs, TRCs, CRFs and ARCs and the NHS. The study will take place in state-of-the-art facilities within our worldleading academic institutions and hospitals within the UK.

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    20/YH/0225

  • Date of REC Opinion

    14 Jul 2020

  • REC opinion

    Further Information Favourable Opinion